Pfizer Ophthalmics and Bausch & Lomb Announce Co-Promotion Agreement Covering Xalatan, Alrex, Lotemax and Zylet
March 4, 2009
Pfizer Inc and Bausch & Lomb announced a co-promotion agreement involving both companies’ prescription ophthalmic pharmaceuticals in the United States. The agreement will allow both companies to greatly increase the level of eye care industry support for these important medications that treat serious ophthalmic conditions.The five-year agreement includes Pfizer’s Xalatan® (latanoprost ophthalmic solution) and Bausch & Lomb’s Alrex® (loteprednol etabonate ophthalmic suspension 0.2%), Lotemax® (loteprednol etabonate ophthalmic suspension 0.5%) and Zylet® (loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension).
The co-promotion agreement also will apply to Bausch & Lomb’s investigational anti-infective eye drop, besifloxacin ophthalmic suspension, 0.6%, which is currently under review by the U.S. Food and Drug Administration (FDA).
Under the terms of the agreement, both the Pfizer and Bausch & Lomb sales forces will promote Xalatan, Alrex, Lotemax, Zylet and besifloxacin (subject to FDA approval).
Read the full release.
You might also enjoy...
- Bausch + Lomb Acquiring ISTA Pharmaceuticals
- FDA Approves Besifloxacin Drops for Treatment of Bacterial Conjunctivitis
- Bausch + Lomb to Distribute Technolas Femtosecond Laser System for Cataract and Refractive Surgery
- NicOx Reacquires Rights to Glaucoma Drug From Pfizer
- InSite Vision Commences Phase 1/2 Clinical Study of ISV-303 for Post-Surgical Ocular Pain and Swelling Following Cataract and Other Surgeries
Comments
Jump down to form below to submit your own comments
